<div id="readability-page-1"><p>Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $241.71 and last traded at $240.93, with a volume of 209368 shares changing hands. The stock had previously closed at $234.64.</p><div><p><span></span><span>Get <strong>Krystal Biotech</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>A number of brokerages have recently weighed in on KRYS. Guggenheim  set a $224.00 target price on Krystal Biotech and gave the company a &#34;buy&#34; rating in a report on Friday, October 17th. Bank of America boosted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, October 17th. Chardan Capital upped their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating and two have issued  a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $228.14.</p><p><b>Read Our Latest Report on KRYS</b></p><h2>Krystal Biotech Price Performance</h2><ul><li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li></ul><p>The stock's 50 day moving average price is $200.23 and its two-hundred day moving average price is $164.51. The firm has a market capitalization of $6.95 billion, a price-to-earnings ratio of 35.94 and a beta of 0.48. </p><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%.  As a group, equities research analysts anticipate that  Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year. </p><h2>Insider Buying and Selling at Krystal Biotech</h2><p>In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own  13.70% of the company's stock. </p><h2>Hedge Funds Weigh In On Krystal Biotech</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group increased its position in shares of  Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares during the period.  Hantz Financial Services Inc. boosted its stake in  Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after buying an additional 179 shares in the last quarter.  Bessemer Group Inc. increased its holdings in  Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company's stock valued at $26,000 after buying an additional 77 shares during the period.  Twin Tree Management LP bought a new position in shares of  Krystal Biotech during the 1st quarter worth about $29,000.  Finally, AdvisorNet Financial Inc bought a new stake in  Krystal Biotech in the third quarter valued at about $30,000. 86.29% of the stock is currently owned by institutional investors. </p><h2>About Krystal Biotech</h2> (Get Free Report)<p>Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Krystal Biotech</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>The Top 3 Investment Themes That Will Dominate 2026</li><li>How to Calculate Options Profits</li><li>Vertical’s Valo Launch: A Commercial Leap Disguised as a Dip</li><li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li><li> Dividend Stocks for 2026: Where to Invest as the Market Cools</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2><p>Before you consider Krystal Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRYS

<p>Krystal Biotech's stock (NASDAQ:KRYS) reached a new 52-week high, trading as high as $241.71. Analysts have given the stock a "Moderate Buy" rating with an average target price of $228.14. Recent earnings exceeded expectations, with a reported EPS of $2.66. Insider Suma Krishnan sold 25,000 shares, and institutional investors have adjusted their stakes. The company focuses on genetic medicines for rare diseases.</p>

Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High - Still a Buy?